Biogen /zigman2/quotes/201531540/composite BIIB -1.71% said it will pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease after consulting with the U.S. Food and Drug Administration. A Phase 3 trial met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients in the study who received sufficient exposure to high dose aducanumab support the finding. The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis.
Read the full story:
Biogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beat